Instead of managing symptoms, the company's mRNA CAR-T therapy eliminates sensitized mast cells. This allows the body to repopulate with new, non-sensitized cells, aiming to permanently reset the immune system's allergic response at its cellular source, a strategy borrowed from cancer immunotherapy.
Unlike permanent gene-editing, the company's mRNA-based CAR-T therapy is transient, with T-cell programming lasting only 7-10 days. This temporary effect enhances safety by avoiding permanent genetic changes and provides crucial flexibility to repeat or adjust dosing to achieve desired durability, much like a traditional drug.
A key challenge in treating mast cell diseases is that the cells are deeply embedded in tissues like the gut and lungs, making them hard for antibody therapies to reach. Allergy and AI's approach uses T-cells, which naturally traffic into tissues, as a delivery mechanism to hunt and eliminate these hard-to-reach targets.
The company's mRNA and lipid nanoparticle (LNP) platform can leverage the massive manufacturing and distribution infrastructure built globally for COVID-19 vaccines. This solves a major scalability bottleneck that plagues traditional cell therapies, making their advanced treatment potentially as accessible and distributable as a vaccine.
While investors see the massive potential in a novel CAR-T approach for allergies, its newness is a double-edged sword. The lack of existing scientific literature means the company must generate more foundational de-risking data itself to provide the comfort investors need, as they can't rely on established public research.
Allergy and AI Therapeutics uses a proprietary AI application to consolidate and query data from thousands of publications and public databases. This allows their team to rapidly answer critical questions about a potential target's expression on normal versus diseased tissue, significantly speeding up the target selection and validation process.